TreatmentMagnetic resonance imagingLaboratory testsThe diagnosis of multiple sclerosis (MS) still rests on the time-honored twin criteria of dissemination in time and space. The disease shows a predilection for certain parts of the central nervous system: the optic nerves and chiasm, the brain stem...
WebMD explains the symptoms and treatment of relapsing-remitting multiple sclerosis, the most common of the four types of MS.
There are four different types of multiple sclerosis that have been identified and each type can have symptoms ranging from mild to severe. The different types of MS can help predict the course of the disease and a patient's response to treatment. The four types of MS are discussed on the ...
Multiple sclerosis (MS) is thought to be an autoimmune disease; however, the exact cause is not known. Early signs and symptoms of MS are fatigue, bladder and bowel problems, vision problems, and numbness, tingling, or pain in certain areas of the body.
Multiple sclerosis (MS) has a worldwide distribution but is five times more common in temperate regions than in tropical regions. Thediseaseprimarily occurs in individuals between ages 20 and 40, and women are affected by the disease more often than men. ...
Although there isn't yet a cure for multiple sclerosis, the many new treatment options around DMTs, better supportive care, and earlier detection have led to greatly improved outcomes for people with MS. However, the biggest challenges doctors face in treating MS are the health risks associated ...
The modern treatment era formultiple sclerosis(MS) began in 1993 with the approval of the first disease-modifying agent. Since then the field has greatly expanded, with 10 therapies currently approved to treatMS. These treatments are effective to reduce relapses and changes on MRI, and slow dis...
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these
W. et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49, 351–357 (1997). PubMed Google Scholar Mundt, S. et al. Conventional DCs sample and present ...
multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjorgen's syndrome; juvenile onset diabetes; and immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes typically found in tuberculosis, sarcoidosis, polymyositis, gran...